Navigation Links
On March 4, 2009, The United States Supreme Court Rejected the Rationale Behind Michigan's Drug Product Liability Law
Date:3/4/2009

DETROIT, March 4 /PRNewswire/ -- On March 4, 2009, the United States Supreme Court in the case of Wyeth v. Levine, rejected the drug company's argument that because it was complying with FDA standards it should be immune from suit. Because of this decision, citizens in all states except Michigan can continue to sue drug companies whose products injure the citizens of those states.

During the term of former Governor John Engler, the Republican legislature passed a statute granting immunity to companies (drug companies) whose products are approved by the FDA. That statute which denied Michigan citizens the right to sue for injuries sustained from dangerous drugs was believed by drug companies to set a pattern which would allow the drug companies to deny the citizens in the other 49 states the right to sue.

Using the theory of "Federal Pre-emption" Wyeth told the United States Supreme Court that under the law it could not change its labeling to warn people such as Mrs. Levine that the Wyeth drug Phenergan by the iv - push method had the potential of causing serious injuries and death, including amputation, because the FDA laws did not allow such a change in the warnings. The United States Supreme Court found this to be untrue after analyzing the existing laws.

Two editorials in the leading medical journals, Journal of the American Medical Association and the New England Journal of Medicine, both criticized the attempts of the drug companies to seek immunity and encouraged the United States Supreme Court not to recognize Federal Pre-emption if it meant preventing state court actions against drug companies. The authors of these editorials pointed to the numerous drug products where drug companies hid information about the dangers of drugs that was only uncovered and made available to the medical profession by the filing of state lawsuits which allowed state courts to order drug companies to turn over documents that the drug companies had either hidden from the FDA or mischaracterized to the FDA.

The decision according to Michigan Trial Lawyer, J. Douglas Peters of Charfoos & Christensen, P.C., "This decision may have a sobering impact on the Republicans in the Michigan Senate which should immediately consider reversing Michigan's unique and unfair law to bring Michigan back into line with the law of the other 49 states, as recognized by the United States Supreme Court in its new decision."

According to Peters, "The drug industry had a special friend in Governor Engler, and Governor Engler tried to export his success for the drug companies in Michigan to the national level where he currently works as a lobbyist for various manufacturing interests."

Peters also stated that he " ... hopes the Michigan legislature will act quickly to change Michigan's consumer hostile drug law in light of this new United States Supreme Court decision, to protect the health, safety and welfare of Michigan citizens."

    For more information contact:
    J. Douglas Peters, Esq.
    Charfoos & Christensen, P.C.
    5510 Woodward Avenue
    Detroit, Michigan  48202
    (313) 875-8080


'/>"/>
SOURCE Charfoos & Christensen, P.C.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Multiple Sclerosis(MS) Awareness Week is March 15-21
2. AMERIGROUP Corporation to Present at the Barclays Capital Global Healthcare Conference on March 10
3. Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
4. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
5. Air Methods to Report Fourth Quarter and Fiscal Year 2008 Financial Results on Tuesday, March 10, 2009
6. PLC Systems to Host Fourth Quarter Conference Call on March 12, 2009
7. Osteotech Announces Fourth Quarter and Full Year 2008 Earnings Release and Conference Call; Company to Release Financial Results on Wednesday, March 4, 2009 and Host Call on Thursday, March 5, 2009
8. China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16
9. EyeCare America Offers No-Cost Medical Eye Care to Qualified Seniors In Support of National AMD Month - March 2009
10. March Is National Kidney Month
11. Triple-S Management Corporation to Host Inaugural Investor Day on March 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... autologous fat (adipose) transfer systems announces the issuance of United States Patent Number ... for its adipose filtration technology. The '398 and '324 patents cover methods ...
(Date:7/24/2017)... Georgia (PRWEB) , ... July 24, 2017 , ... ... comprehensive sleep management solution focused on delivering end-to-end sleep health care ... program. , Recent literature shows that adherence rates for positive airway pressure (PAP) ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to ... have enrolled over 100,000 children in their treatment program. Clubfoot is a pervasive ... areas where treatment is limited or non-existent. Without intervention, these children are destined ...
(Date:7/24/2017)... Shandong Province (PRWEB) , ... July 24, 2017 ... ... Chinese Medicine's "Chinese Medicine Clinical Vitiligo Hospital" was set up, and the awarding ... Administration of traditional Chinese medicine, the head of the army's health system, and ...
(Date:7/24/2017)... ... 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir ... of published author, Ed Clark. Ed Clark is a church music director and ... a minister of music and worship leader for over fifty years. He has ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)...  The tenth annual BioPharm America™ will ... at the Sheraton Boston Hotel, September 26–27. The event ... decision makers and innovative biotech startup companies. The event ... two impactful days. BioPharm America is now part of ... opportunities with 4,500+ life science industry influencers participating in ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: